Irene Martínez-Díaz, Nerea Martos, Carmen Llorens-Cebrià, Francisco J Álvarez, Patricia W Bedard, Ander Vergara, Conxita Jacobs-Cachá, Maria José Soler
Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines. In this context, ET, via the endothelin receptor type A (ETA ) activation, causes sustained vasoconstriction of the afferent arterioles that produces deleterious effects such as hyperfiltration, podocyte damage, proteinuria and, eventually, GFR decline. Therefore, endothelin receptor antagonists (ERAs) have been proposed as a therapeutic strategy to reduce proteinuria and slow the progression of kidney disease...
February 8, 2023: International Journal of Molecular Sciences